Analyst Price Target is $53.33
▲ +68.78% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Mirum Pharmaceuticals in the last 3 months. The average price target is $53.33, with a high forecast of $84.00 and a low forecast of $30.00. The average price target represents a 68.78% upside from the last price of $31.60.
Current Consensus is
The current consensus among 5 investment analysts is to buy stock in Mirum Pharmaceuticals. This Buy consensus rating has held steady for over two years.
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of primary sclerosing cholangitis and primary biliary cholangitis in adults. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.